In a recent exclusive interview, Fierce Biotech’s Chris Hayden sat down with Alex MacDonald, Vice President of Model-Informed Drug Development at Allucent, to explore the impact of Project Optimus, an ...
Ametris (formerly ActiGraph) has launched its second Digital Endpoint Collaboration Outcome Development (DECODE) working group for the purpose of enhancing drug development for obesity. The ...
When pharmaceutical companies develop a novel drug for the market, several steps are required to assess and regulate its safety, effectiveness, manufacturability, and reliability. These processes, and ...
TUCSON, Ariz., June 18, 2025 — Critical Path Institute’s® (C-Path) Translational Therapeutics Accelerator (TRxA) proudly announced today a $250,000 grant award aimed at developing a novel treatment ...
TUCSON, Ariz., November 19, 2024 — Critical Path Institute® (C-Path) today announced that its Translational Therapeutics Accelerator (TRxA) program, in partnership with The Leona M. and Harry B.
The pharmaceutical industry invests heavily in technologies—$57.4 billion in 2022 alone—to discover new therapies to treat our greatest health challenges. Yet drug development teams are still using ...
Improved understanding of regulatory requirements by academic researchers can accelerate the translation of new medical interventions to the clinic. Here, we highlight the recommendations of the ...
Companies operating in the pharmaceutical and biotech sectors must evaluate a range of critical factors prior to partnering with a contract development and manufacturing organization (CDMO). Selecting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback